Leerink Partners Keeps Their Hold Rating on SAGE Therapeutics (SAGE)

Leerink Partners analyst Marc Goodman maintained a Hold rating on SAGE Therapeutics (SAGEResearch Report) on May 20. The company’s shares closed last Friday at $74.41.

According to TipRanks.com, Goodman is a 3-star analyst with an average return of 3.9% and a 50.6% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Intra-Cellular Therapies, and Satsuma Pharmaceuticals.

SAGE Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $103.00, which is a 38.2% upside from current levels. In a report issued on May 20, Raymond James also maintained a Hold rating on the stock.

See today’s analyst top recommended stocks >>

Based on SAGE Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $1.58 million and GAAP net loss of $95.76 million. In comparison, last year the company earned revenue of $2.29 million and had a GAAP net loss of $127 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.